Navigation Links
HistoRx Receives Fundamental Patent on Standardization of Results In Digital Pathology

BRANFORD, Conn., March 21, 2011 /PRNewswire/ -- HistoRx, Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for standardization of digital microscopy instruments in order to go beyond imaging to generating high-quality reproducible data that precisely relates to biomarker concentrations in tissue sections.

Digital pathology involves taking digital pictures of an anatomic pathology specimen, a slide with cells or a thinly-sliced piece of tissue, and managing the interpretation and storage of the resulting images.  While most companies involved in digital pathology emphasize generation and storage of images for interpretation, HistoRx is the only company to bring reproducibility, or standardization, to those images, to quantify protein in tissue for accurate biomarker measurement.

"This patent covers HistoRx's unique ability to ensure that multiple instruments performing the same test, whether in one or many locations, can give the same result for a patient's slide," said Jason Christiansen, Senior Director of Operations at HistoRx and the lead inventor.  "We don't make digital microscopy systems, we make digital microscopy systems better."

Quantitative IHC (qIHC) is only as good as the image from which the data is derived.  Robust quantitative data can only be achieved from reproducible images, generated with information from standardized digital microscopy instruments.  HistoRx is the first company to address standardization of digital microscopy instruments to deliver high quality reproducible data that precisely relates to biomarker concentrations in tissue sections -- data that is essential to the development and delivery of personalized cancer care.

The patented approach applies to qIHC, as well as all uses of digital microscopy and establishes the definition for standardization and reproducibility in both brightfield and fluorescent digital pathology.

U.S. Patent No. 7,907,271 is the first assigned to HistoRx and is entitled "Method and System for Standardizing Microscope Instruments."  Inventors Jason Christiansen, Robert Pinard, Maciej Zerkowski and Greg Tedeschi are all current or former employees of the company.

AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.  Such precise determination of first, the location within the tumor cell and second, the amount in each location is not possible with any other method, digital or otherwise.  AQUA analysis is used in cancer research by twenty leading academic centers worldwide, is part of the clinical development plans for more than ten drug candidates from major pharma companies, and has been cited in more than 90 peer-reviewed publications.  The first use of AQUA technology in the clinical diagnostic setting occurred in 2010 with the launch by Genoptix Inc. (a subsidiary of Novartis) of diagnostic tests based on AQUA technology licensed from HistoRx. AQUA technology is currently available on the ScanScope FL™ from Aperio and will be available later this year on the Nuance™ and Vectra™ systems from Caliper Life Sciences.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology.  AQUA® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care.  For more information, please visit

SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
2. HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council
3. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
4. Caliper Life Sciences and HistoRx to Provide Integrated Solutions for Superior Protein Quantification of Biomarkers in Tissue
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
(Date:11/25/2015)... -- Developmental, commercial, and regulatory/legal strategies ... pharmaceutical products, says GBI Research . ... all play a key role in boosting the profitability ... . --> Developmental, commercial, and ... the profitability of pharmaceutical products, says GBI Research ...
(Date:11/25/2015)... Frankreich, November 25, 2015 ... dass sie eine Lizenz für das Patent über eine ... UCBL und ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... AAP8 ins Leben gerufenen und von Edelris gemeinsam mit ... als ein Behandlungsziel für HBV identifiziert, und es wurden ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... accessible for all, Water For Empowerment ™ attracts volunteers together who want ... water by empowering women as key stakeholders in the process. The non-profit launched ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 ... ... manufacturer, launched offering factory direct sauna parts and accessories. , Sauna accessories ... representative of the bather’s style and personality. From basic styles for the purist ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... OK (PRWEB) , ... November 25, 2015 , ... On ... International training center for the Narconon network, announced the release of a new cutting ... 1966 the Narconon organization has been working with drug- and alcohol-addicted individuals with the ...
Breaking Medicine News(10 mins):